M&A activity, IPOs and late-stage investments gain momentum as investors prioritize clinical validation, while early-stage biotech firms continue to face funding challenges
Prior to joining Cipla, Gambhir built a strong track record across the pharmaceutical and healthcare sectors.
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
The acquisition of Milan-based company will strengthen subsidiary Alivira Animal Health’s presence in Europe
Clara Sattler de Sousa e Brito to lead discovery solutions from Q3 2026, while Robert Machinek takes over as Head of Strategy & Business Development
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
New PARTNER trial sub-study data show that post-operative ctDNA detection using tumour-informed MRD assays can accurately predict distant recurrence risk in triple-negative breast cancer patients
Veteran pharmaceutical executive to relocate to Saudi Arabia and spearhead Cipla’s growth strategy across the Middle East region
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
